Retatrutide Research
Share
All articles and product details on this website are provided solely for informational and educational purposes. Our products are not drugs and have not been evaluated or approved by the FDA to diagnose, treat, prevent, or cure any disease or medical condition. These materials are intended exclusively for laboratory research use. Any form of human or animal consumption, application, or bodily introduction is strictly prohibited by law.
Top 30 articles on Reta from the National Library of Medicine
1.
Appetite, eating attitudes, and eating behaviours during treatment with retatrutide in adults with type 2 diabetes: Results of a phase 2 study.
- Kanu C, Boye KS, Poon JL, Goetz I, Williamson S, Lou J, Hartman ML, Martin CK, Coskun T.
- Diabetes Obes Metab. 2025 Sep 8;27(12):6988-6998. doi: 10.1111/dom.70097.
- PMCID: PMC12587234
Improvements from baseline versus placebo in EI Perceived Hunger and Disinhibition were greater in participants who received retatrutide 8 and 12 mg at Weeks 24 and 36. Dietary Restraint increased from baseline versus placebo only in participants who received retatrutid …
-
2.Decreases in circulating ANGPTL3/8 concentrations following retatrutide treatment parallel reductions in serum lipids.- Wen Y, Lemen D, Lin Y, Chen YQ, Regmi A, Roell WC, Thomas MK, Hartman ML, Coskun T, Milicevic Z, Haupt A, Ruotolo G, Konrad RJ.
- Diabetes Obes Metab. 2025 Jul 29;27(10):5985-5995. doi: 10.1111/dom.16661.
- PMCID: PMC12409240
RESULTS: ANGPTL3/8 reductions were observed with 8 and 12 mg retatrutide doses in participants with type 2 diabetes, and with 1, 4, 8 and 12 mg retatrutide doses in participants with obesity or overweight but without diabetes. In both cases, ANGPTL3/8 decreases para … -
3.Retatrutide-A Game Changer in Obesity Pharmacotherapy.- Katsi V, Koutsopoulos G, Fragoulis C, Dimitriadis K, Tsioufis K.
- Biomolecules. 2025 May 30;15(6):796. doi: 10.3390/biom15060796.
- PMCID: PMC12190491
Ongoing Phase III trials, such as the TRIUMPH studies, aim to further evaluate retatrutide's long-term safety and efficacy in diverse patient populations. While retatrutide shows immense promise, considerations regarding cost and the quality of weight loss beyond BM … -
4.Retatrutide improves steatohepatitis in an accelerated mouse model of diet-induced steatohepatitis with a fructose binge.- Viebahn GK, Khurana A, Freund L, Chilin-Fuentes D, Jepsen K, Rosenthal SB, Chatterjee S, Ellenrieder V, Hsu CL, Schnabl B, Hartmann P.
- Am J Physiol Gastrointest Liver Physiol. Author manuscript. 2025 Oct 7;329(6):G680-G695. doi: 10.1152/ajpgi.00164.2025.
- PMCID: PMC12643026
Fructose consumption contributes to metabolic dysfunction-associated steatohepatitis (MASH). Retatrutide is a novel triple receptor agonist that improves obesity and hepatic steatosis in humans. The aims of this study were to develop a shortened and clinically relevant die … -
5.Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.- Sanyal AJ, Kaplan LM, Frias JP, Brouwers B, Wu Q, Thomas MK, Harris C, Schloot NC, Du Y, Mather KJ, Haupt A, Hartman ML.
- Nat Med. 2024 Jun 10;30(7):2037-2048. doi: 10.1038/s41591-024-03018-2.
- PMCID: PMC11271400
Retatrutide is a novel triple agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1 and glucagon receptors. A 48-week phase 2 obesity study demonstrated weight reductions of 22.8% and 24.2% with retatrutide 8 and 12 mg, respectively. T … -
6.Pharmacological Dissection Identifies Retatrutide Overcomes the Therapeutic Barrier of Obese TNBC Treatments through Suppressing the Interplay between Glycosylation and Ubiquitylation of YAP.- Cui X, Zhu Y, Zeng L, Zhang M, Uddin A, Gillespie TW, McCullough LE, Zhao S, Torres MA, Wan Y.
- Adv Sci (Weinh). 2025 Jan 27;12(11):e2407494. doi: 10.1002/advs.202407494.
- PMCID: PMC11923992
This aberrant upregulation of HBP promotes YAP O-GlcNAcylation and the subsequent recruitment of EIF3H deubiquitinase, which stabilizes YAP, thus promoting tumor growth and chemotherapy resistance. It is found that Retatrutide, an anti-obesity agent, inhibits HBP and YAP O … -
7.Perceived benefits of treatment for obesity with retatrutide: A qualitative study of patients in a phase 2 clinical trial.- Goetz IA, Kanu C, Hoover A, Jimenez-Moreno C, Karn H, Kimel M, Neff LM, Boye KS.
- Obes Pillars. 2025 Oct 24;16:100220. doi: 10.1016/j.obpill.2025.100220.
- PMCID: PMC12596213
RESULTS: Participants (N = 40; mean age 51 years; 52.5 % male) received retatrutide 4/8/12 mg (n = 23), retatrutide 1 mg (n = 13), or placebo (n = 4). Thirty-one of 36 retatrutide-treated participants reported changes in eating behaviors within the trial's fi … -
8.SUN-659 Comparative Efficacy and Safety of Tirzepatide vs Retatrutide in Weight Loss: A Network Meta-Analysis of Clinical Trials.- Salhab A, Maraqah H, Habes Y, Abusabha M, Ayesh H.
- J Endocr Soc. 2025 Oct 22;9(Suppl 1):bvaf149.169. doi: 10.1210/jendso/bvaf149.169.
- PMCID: PMC12544991
Outcomes included absolute and percentage weight change and adverse events. Results: Retatrutidedemonstrated greater absolute weight reduction compared to tirzepatide (Retatrutide: MD -16.34 kg, 95% CI [-22.11; -10.56], p < 0.0001; Tirzepatide: MD -11.82 kg, 95%
… -
9.7792 Efficacy of Retatrutide for Weight Reduction and Its Cardiometabolic Effects Among Adults: A Systematic Review and Meta-Analysis.- Lopez DC, Pajimna JT, Milan MD, Jasul GV, Orpilla G, Zapanta I, Serquiña B, Dychiao G.
- J Endocr Soc. 2024 Oct 5;8(Suppl 1):bvae163.749. doi: 10.1210/jendso/bvae163.749.
- PMCID: PMC11453264
Using direct comparison, retatrutide 12mg reduced body weight by 11.83kg as compared to dulaglutide 1.5mg with significant difference (MD -11.83; 95% CI -18.50 to -5.16), and retatrutideshowed slight decrease in HbA1C by 0.61% as compared to dulaglutide (MD -0.66; … -
10.Effects of once-weekly subcutaneous retatrutide on weight and metabolic markers: A systematic review and meta-analysis of randomized controlled trials.- Pasqualotto E, Ferreira ROM, Chavez MP, Hohl A, Ronsoni MF, Pasqualotto T, Moraes FCA, Hespanhol L, Figueiredo Watanabe JM, Lütkemeyer C, van de Sande-Lee S.
- Metabol Open. 2024 Sep 13;24:100321. doi: 10.1016/j.metop.2024.100321.
- PMCID: PMC11420505
RESULTS: A total of three studies were included, comprising 640 patients, of whom 510 were prescribed retatrutide. Compared with placebo, retatrutide significantly reduced body weight (WMD -10.66 kg; 95 % CI -17.63, -3.69), body mass index (WMD -4.53 kg/m(2); 95 % C …
-
11.The "Weight" for a New Agent Is Almost Over: A Commentary on the Novel Triagonist Retatrutide for Obesity.- Deravi M, Piszczatoski C, Phillips B, Huston J, Vascimini A.
- J Pharm Technol. 2024 Oct 19;40(6):300-305. doi: 10.1177/87551225241285326.
- PMCID: PMC11536522
Retatrutide, a hormone receptor agonist targeting glucagon, glucagon-like peptide 1, and glucose-dependent insulinotropic polypeptide, is being developed to treat obesity. ...Ongoing phase II and III studies aim to further evaluate the safety and efficacy of retatrutide … -
12.Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials.- Abdrabou Abouelmagd A, Abdelrehim AM, Bashir MN, Abdelsalam F, Marey A, Tanas Y, Abuklish DM, Belal MM.
- Proc (Bayl Univ Med Cent). 2025 Feb 5;38(3):291-303. doi: 10.1080/08998280.2025.2456441.
- PMCID: PMC12026077
BACKGROUND: Retatrutide is a novel triple agonist targeting the receptors of glucagon-like peptide 1 (GLP-1), gastric inhibitory polypeptide (GIP), and glucagon. We sought to assess the efficacy and safety of retatrutide in obese patients with or without diabetes. M … -
13.Unleashing the power of retatrutide: A possible triumph over obesity and overweight: A correspondence.- Naeem M, Imran L, Banatwala UESS.
- Health Sci Rep. 2024 Feb 5;7(2):e1864. doi: 10.1002/hsr2.1864.
- PMCID: PMC10844714
The primary focus of this paper is to explore retatrutide and critically assess its clinical trials to justify its use and feasibility while highlighting its shortcomings. ...CONCLUSION: It is expected that the use of retatrutide, a triple agonist, will result in si … -
14.The Effect of Retatrutide on Kidney Parameters in Participants With Type 2 Diabetes Mellitus and/or Obesity.- Heerspink HJL, Lu Z, Du Y, Duffin KL, Coskun T, Haupt A, Hartman ML.
- Kidney Int Rep. 2025 Apr 2;10(6):1980-1992. doi: 10.1016/j.ekir.2025.03.049.
- PMCID: PMC12231004
This study assessed changes in kidney parameters with retatrutide, an agonist of the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors. METHODS: A post hoc analysis of 2 retatrutide studies (dose range: 0.5-1 … -
15.Triple Agonism Based Therapies for Obesity.- Goldney J, Hamza M, Surti F, Davies MJ, Papamargaritis D.
- Curr Cardiovasc Risk Rep. 2025 Jul 28;19(1):18. doi: 10.1007/s12170-025-00770-z.
- PMCID: PMC12304053
This review outlines the rationale for their development and summarizes clinical trial data, focusing on retatrutide, the most advanced candidate. RECENT FINDINGS: Retatrutide is the first triple agonist (acting on GLP-1/GIP/glucagon receptors) with published phase … -
16.SUN-654 Comparative Efficacy and Safety of Glucagon Receptor Agonists in Metabolic Outcomes: A Network Meta-Analysis of Randomized Controlled Trials.- Abulehia A, Ayesh H, Itbaisha A, Jaber D, Abugharbieh H, Andonie CR.
- J Endocr Soc. 2025 Oct 22;9(Suppl 1):bvaf149.164. doi: 10.1210/jendso/bvaf149.164.
- PMCID: PMC12544732
The emergence of dual glucagon/GLP-1 receptor agonists, such as survodutide, cotadutide, retatrutide, and mazdutide, introduces a novel therapeutic paradigm. Despite promising outcomes, limited comparative evidence exists among these agents. ...Conclusions: Retatrutide< … -
17.Retatrutide.- Ramsbacher N.
- Clin Diabetes. 2024 Aug 1;42(4):579-580. doi: 10.2337/cd24-0062.
- PMCID: PMC11486854
-
18.Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide.
- Li W, Zhou Q, Cong Z, Yuan Q, Li W, Zhao F, Xu HE, Zhao LH, Yang D, Wang MW.
- Cell Discov. 2024 Jul 17;10(1):77. doi: 10.1038/s41421-024-00700-0.
- PMCID: PMC11255275
-
19.Evaluating the Impact of Novel Incretin Therapies on Cardiovascular Outcomes in Type 2 Diabetes: An Early Systematic Review.
- Salmen T, Potcovaru CG, Bica IC, Giglio RV, Patti AM, Stoica RA, Ciaccio M, El-Tanani M, Janež A, Rizzo M, Gherghiceanu F, Stoian AP.
- Pharmaceuticals (Basel). 2024 Oct 3;17(10):1322. doi: 10.3390/ph17101322.
- PMCID: PMC11510241
Background This systematic review is registered with CRD42024507397 protocol number and aims to compare the known data about retatrutide on long-term cardiovascular (CV) protection with tirzepatide, an incretin with recent proven CV benefits. ...Studies were selected if th … -
20.The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update.- Jakubowska A, Roux CWL, Viljoen A.
- Endocrinol Metab (Seoul). 2024 Feb 14;39(1):12-22. doi: 10.3803/EnM.2024.1942.
- PMCID: PMC10901658
The 2023 phase 2 double-blind, randomized controlled trial evaluating a GLP-1/GIP/glucagon receptor triagonist (retatrutide) in patients with the disease of obesity reported 24.2% weight loss at 48 weeks with 12 mg retatrutide. ... -
21.Association between patient-reported eating behaviours and weight change: Secondary analyses of a randomized, double-blind trial comparing retatrutide and placebo in people with obesity or overweight.
- Kanu C, Wu Q, Poon JL, Goetz I, Perez-Nieves M, Boye K, Martin CK, Coskun T, Hartman ML.
- Diabetes Obes Metab. 2025 Jul 30;27(10):6088-6091. doi: 10.1111/dom.16662.
- PMCID: PMC12409224
-
22.The Effects of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists on Polycystic Ovarian Syndrome: A Scoping Review.
- Hudanich M, Smith SN, Marino A, Riskin SI.
- Cureus. 2025 Sep 24;17(9):e93104. doi: 10.7759/cureus.93104.
- PMCID: PMC12551431
The aim of this review was to explore the classes of incretin mimetics, such as glucagon-like peptide-1 (GLP-1) receptor agonists or semaglutide, dual agonists of the GLP-1 receptor and gastric inhibitory peptide (GIP) or tirzepatide, and a new triple agonist, or retatrutide … -
23.Beyond GLP-1: efficacy and safety of dual and triple incretin agonists in personalized type 2 diabetes care-a systematic review and network meta-analysis.- Yan K, Yu H, Blaise B.
- Acta Diabetol. 2025 Jun 5;62(9):1359-1370. doi: 10.1007/s00592-025-02534-y.
- PMCID: PMC12433336
DATA EXTRACTION: Data on efficacy and safety were extracted by independent reviewers and assessed for quality using the NIH Quality Assessment Tool. DATA SYNTHESIS: Retatrutide achieved the greatest weight reduction (MD: - 8.601; 95% CrI: - 11.20 to - 5.95) while Tirzepati … -
24.Incretin triple agonist retatrutide (LY3437943) alleviates obesity-associated cancer progression.- Marathe SJ, Grey EW, Bohm MS, Joseph SC, Ramesh AV, Cottam MA, Idrees K, Wellen KE, Hasty AH, Rathmell JC, Makowski L.
- NPJ Metab Health Dis. 2025 Mar 14;3(1):10. doi: 10.1038/s44324-025-00054-5.
- PMCID: PMC11908972
We report that in pre-clinical models with significant retatrutide (RETA, LY3437943)-induced weight loss, pancreatic cancer engraftment was reduced, tumor onset was delayed, and progression was attenuated resulting in a 14-fold reduction in tumor volume compared to only 4- … -
25.Future is Brighter: New Potential Paradigm-Shifting Medications and Regimens for Diabetes and Obesity.- Al-Horani RA, Aliter KF, Aliter HF.
- Curr Diabetes Rev. Author manuscript. 2024;20(8):84-97. doi: 10.2174/0115733998276832231124170324.
- PMCID: PMC11452264
For type 1 diabetes mellitus (T1DM), they include teplizumab, ustekinumab, jakinibs, and cell therapies, whereas for type 2 diabetes mellitus (T2DM), they include once-weakly insulin, tirzepatide, high oral dose of semaglutide, orforglipron, retatrutide, CagriSema, and sur … -
26.Review: Special Issue: Real-world evidence on the use of GLP1 receptor agonists: Emerging concepts in obesity management: focus on glucagon receptor agonist combinations.- Anderson SL.
- Drugs Context. 2025 Jul 24;14:2025-4-8. doi: 10.7573/dic.2025-4-8.
- PMCID: PMC12306892
Agents like mazdutide, pemvidutide, survodutide and retatrutide have demonstrated the ability to trigger significant weight loss in earlier phase trials, often surpassing the amount of weight loss obtained with existing therapies. ... -
27.Top studies of 2023 relevant to primary care: From the PEER team.- Thomas BS, Perry D, Moe SS, Turgeon RD, Potter J, Braschi É, Dugré N, Kirkwood JEM, Allan GM.
- Can Fam Physician. 2024 Apr;70(4):245-248. doi: 10.46747/cfp.7004245.
- PMCID: PMC11280662
Two "up and coming" medications are also mentioned: retatrutide for weight loss and fezolinetant for vasomotor symptoms of menopause. CONCLUSION: Research published in 2023 yielded several high-quality articles with topics relevant to primary care, including cardiovascular … -
28.Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now?- Gogineni P, Melson E, Papamargaritis D, Davies M.
- Expert Opin Pharmacother. 2024 May 22;25(7):801-818. doi: 10.1080/14656566.2024.2356254.
- PMCID: PMC11195668
AREAS COVERED: Herein, we review the data on (i) oral GLP-1 RAs (oral semaglutide 25/50 mg and orforglipron) and (ii) dual/triple agonists (tirzepatide, cagrilintide 2.4 mg/semaglutide 2.4 mg, survodutide, mazdutide, retatrutide) that have recently completed phase 3 trials … -
29.Evaluating the Rates of Pancreatitis and Pancreatic Cancer Among GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.- Wen J, Nadora D, Bernstein E, How-Volkman C, Truong A, Joy B, Kou M, Muttalib Z, Alam A, Frezza E.
- Endocrinol Diabetes Metab. 2025 Sep;8(5):e70113. doi: 10.1002/edm2.70113.
- PMCID: PMC12457091
RESULTS: 62 studies utilising dulaglutide, exenatide, liraglutide, semaglutide, beinaglutide, retatrutide, or tirzepatide, with 66,232 patients, mean age of 58.3 years (14.4 to 68), and mean follow-up of 43.5 weeks (1 to 198) were included in this study. ... -
30.Efficacy and safety of anti-obesity drugs in metabolic dysfunction-associated steatotic liver disease: An updated review.- Concepción-Zavaleta MJ, Fuentes-Mendoza JM, Gonzáles-Yovera JG, Ruvalcaba-Barbosa GY, Cura-Rodríguez LD, González-Rodríguez JS, Concepción-Urteaga LA, Pérez-Reyes AI, Quiroz-Aldave JE, Paz-Ibarra J.
- World J Gastroenterol. 2025 Oct 7;31(37):111435. doi: 10.3748/wjg.v31.i37.111435.
- PMCID: PMC12476660
Tirzepatide, a dual GLP-1/GIP agonist, has shown superior weight loss effects compared to GLP-1 receptor agonist monotherapy, with emerging but still limited data on hepatic outcomes in MASLD/MASH. Retatrutide, a triple agonist, has produced the most pronounced metabolic e …